Amplification of MLL perturbs haematopoiesis and cooperates with MLL partial tandem duplication to induce acute myeloid leukaemia : 1
Acquired factor XIII deficiency - an under investigated disorder : 2
An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL): On behalf of the NCRI CLL sub-group : 3
Characterisation of a genetic disease modifier locus in patients with sickle cell anaemia : 4
Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant : 5
Gene- and microRNA- expression signatures of good prognosis in B-cell precursor acute lymphoblastic leukaemia : 6
Clinical predictors of adverse outcome in VTE outpatients - the VERITY PUSH study : 7
Identification of non-carrier mothers of patients with haemophilia A or B: Counselling implications for future offspring : 8
Plasma factor VII a potential marker of pre-eclampsia : 9
Anti-ADAMTS13 IgG antibody subclasses in thrombotic thrombocytopenic purpura and changes with rituximab therapy : 10
Early coagulopathy is associated with increased mortality and re-bleeding in non-cirrhotics with acute upper gastrointestinal bleeding : 11
Effectiveness of prophylactic treatment in preventing thromboembolic events in medical subgroups: A meta-analysis of randomised clinical trials : 12
Performance assessment of newborn sickle screening in the UK : 13
Over-expression of LIN28B is correlated with prognosis in juvenile myelomonocytic leukaemia patients and involves an additional mechanism of RAS-signalling pathway activation : 14
Primary CNS lymphoma in children and adolescents: A descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG) : 15
Changes in paediatric anticoagulant care as a result of the introduction of an anticoagulant nurse practitioner : 16
Sequential acquisition of BCR-ABL1 fusion and IKAROS deletion in Philadelphia chromosome positive ALL : 17
Abstract withdrawn. : 18
Terminal complement inhibitor eculizumab improves complement-mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH) : 19
A prospective observational study evaluating changes in coagulation parameters in trauma admissions : 20
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone : 21
Fetomaternal alloimmune thrombocytopenia (FMAIT) in the UK: A prospective national study of incidence and outcomes using obstetric, paediatric and laboratory reporting systems : 22
Nocturnal haemoglobin oxygen saturation variability is associated with vitamin C deficiency in Tanzanian children with sickle cell anaemia : 23
A spontaneous reduction of clone size in paroxysmal nocturnal haemoglobinuria patients treated with eculizumab for greater than 12 months : 24
A comparison of rivaroxaban and fragmin prophylaxis after high risk orthopaedic surgery on thrombin generation test : 25
Lower doses of prothrombin complex concentrate achieve emergency reversal of warfarin : 26
Identification of deletion mutations in the factor VIII gene of affected males and female carriers of haemophilia A using multiplex ligation-dependent probe amplification (MLPA) : 27
Heparin resistance and antithrombin deficiency : 28
Implementation of British Committee for Standards in Haematology (BCSH) Guidelines: Data from two UK NEQAS (Blood Coagulation) questionnaires : 29
Thrombotic thrombocytopenic purpura associated with statin therapy : 30
WT1 peptide vaccination in poor risk adult AML patients induces WT1-specific immune responses: Results of a leukaemia research supported phase I clinical trial, WTPV-001 : 31
A Cre/Lox model of leukaemia initiation and maintenance : 32
Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials : 33
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukaemia is dependent on FLT3/ITD status : 34
Non-cycling cells from acute myeloid leukaemia patients harbor the FLT3-ITD (FMS-like tyrosine kinase 3- internal tandem duplication) mutation and exhibit in vitro insensitivity to TKI258, a potent FLT3-directed inhibitor : 35
The epigenetic therapies azacitidine and sodium valproate induce immune responses to the MAGE cancer testis antigen in patients with acute myeloid leukaemia achieving a complete remission : 36
Large scale screening for DNA damage-induced transcription factors as potential targets for treatment of ATM/TP53 mutant CLL with p53 apoptotic defect : 37
KIR genotype is associated with progression free and overall survival following autologous stem cell transplantation for multiple myeloma : 38
Predicting clinical outcome in early stage chronic lymphocytic leukaemia (CLL): A multi-centre study of 1153 patients : 39
Dual inhibition of phosphoinositide 3-kinase (PI3K) and mTOR signalling selectively induces apoptosis in multiple myeloma cells expressing the t(4;14) translocation : 40
Achieving minimal residual disease (MRD) negativity in CLL is independently associated with improved progression-free and overall survival and is an appropriate end-point of therapy : 41
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced intensity conditioning : 42
Arsenic trioxide and stem cell transplantation is an effective salvage therapy in patients with relapsed APL : 43
Refractory anaemia with ringed sideroblasts (RARS) are characterized by a deregulation of iron related genes : 44
EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib : 45
Monoclonal gammopathy following allogeneic haematopoietic stem cell transplantation: A frequent finding associated with alemtuzumab T-cell depletion : 46
Evidence of a cell-dose effect in extracorporeal photopheresis therapy of chronic graft versus-host disease : 47
The impact of second generation tyrosine kinase inhibitors on the outcome of allogeneic stem cell transplantation for chronic myeloid leukaemia : 48
Promoting a positive patient experience in haematology with the development of care pathways : 49
UK Systemic Mastocytosis registry: Analysis of data on 95 cases : 50
An audit to determine the patient's perspective of specialist nurses running myeloproliferative clinics : 51
Erythropoietin-induced activation of Rho/ROCK/MLC2 in a model of tumourigenesis : 52
Anticoagulant therapy: Staff training using e-learning. The West Suffolk Hospital NHS Trust experience : 53
Ability of holotranscobalamin assay (Active B12) to detect severe cobalamin deficiency evidenced by high methylmalonic acid in the presence of high titre intrinsic factor antibody and false normal B12 results : 54
Acute venous thrombosis treatment in pregnancy. A multi centre report from Iran over 6 years : 55
Perinatal management of babies with haemophilia : 56
Promoting warfarin safety in hospitalised patients: A multidisciplinary approach : 57
Safe and effective evaluation of the international normalised ratio (INR) by point of care testing in patients on oral vitamin K antagonists prior to cardiac procedures : 58
Establishing a nurse-led electronic thrombophilia service in a district hospital : 59
Superficial venous thrombosis: Single-centre experience of management and outcomes : 60
VerifyNow® P2Y12 assay for thienopyridine resistance: Single-centre experience : 61
Review of all deaths due to pulmonary embolism (PE), identified at autopsy, over 12 months, within a large teaching hospital : 62
The use of coagulation tests in the preoperative assessment of bleeding risk : 63
Patients under 45 years of age attending a district general hospital outpatient deep vein thrombosis clinic: Characteristics and management : 64
Outpatient diagnosis of deep vein thrombosis in pregnant women : 65
Large scale snap-shot audits of venous thromboembolism (VTE) prophylaxis within an exemplar centre demonstrates very good application : 66
Pre-operative fibrinogen level is predictive of perioperative bleeding : 67
Audit of D-dimer levels in the diagnosis of venous thrombo-embolism : 68
Audit of hospital-acquired thrombosis in a district general hospital : 69
A retrospective, radiology audit of venous thromboembolism in all hospitalized adult patients, over a six month period, within a large teaching hospital : 70
Levels of circulating microparticles in patients with gynaecological malignancy - a case-control study : 71
Evaluation of the Multiplate® whole blood platelet aggregometer: normal ranges and diurnal variation assessed in healthy volunteers : 72
Case report of a homozygous 20209C>T substitution in 3′ UTR of the prothrombin gene : 73
Evaluation of an automated platelet-based assay of von Willebrand ristocetin cofactor activity : 74
Nitric oxide indirect markers in mild and severe forms of pre-eclampsia : 75
Increased plasma thrombomodulin levels in pre-eclampsia: Endothelial damage or renal insufficiencies? : 76
Changes in fibrinolytic parameters in pre-eclampsia : 77
Fibrinolytic markers in patients undergoing haemodialysis : 78
Improving venous thromoboembolism prophylaxis in medical inpatients : 79
Lemierre's Syndrome - the forgotten disease? : 80
Thrombin generation: Diurnal variation of measured parameters during the working day : 81
Use of an ADAMTS-13 activity ELISA kit to monitor treatment in a patient with congenital thrombotic thrombocytopenic purpura [TTP], : 82
An audit of patients over age 90 attending the anticoagulant service at the University Hospital of South Manchester : 83
A multiple cycle audit for improving thromboprophylaxis : 84
The effect of exogenous antithrombin on measurement of anti-Xa activity : 85
Heparin-induced thrombocytopenia: The 4Ts in ICU : 86
A retrospective audit of extended low molecular weight heparin (LMWH) therapy in patients deemed unsuitable for warfarin at a large district general hospital : 87
Use of the thrombin generation assay (calibrated automated thrombogram) in enoxaparin (low molecular weight heparin) treated pregnant patients : 88
F8 and F9 mutations fail to co-segregate in a family with co-incident haemophilia A and B : 89
Use of the thrombin generation assay (calibrated automated thrombogram) in patients with multiple myeloma and mantle cell lymphoma on thalidomide or lenalidamide therapy : 90
Compliance with BCSH guidelines on inferior vena cava (IVC) filter insertion : 91
Basal tissue factor levels are higher in patients with mantle cell lymphoma prior to lenalidamide therapy compared to controls : 92
Treatment and complications of high international normalised ratios due to oral anticoagulation. An audit of practice of a large anticoagulation service : 93
An audit of 80 patients between ages 85 and 90 attending the anticoagulant service at the University Hospital of South Manchester : 94
Detecting sepsis beyond the activated partial thromboplastin time waveform : 95
Clinical significance of differences between INR methods in over-anticoagulated patients : 96
Lupus associated catastrophic antiphospholipid syndrome complicated by marantic endocarditis : 97
Audit of vitamin K therapy for reversal of excessive anticoagulation : 98
Newly diagnosed multiple myeloma (MM) patients requiring salvage therapy prior to high dose therapy (HDT) have equivalent progression free survival and overall survival to those receiving a single induction regimen : 99
Bendamustine in relapsed or refractory indolent lymphoproliferative disorders - a single centre experience : 100
Efficacy and safety of single-agent lenalidomide for relapsed/refractory mantle cell lymphoma (MCL): Preliminary results from a UK-based open-label phase II trial : 101
Minimal residual disease monitoring in adult acute lymphoblastic leukaemia in the UK; a multi-centre laboratory feasibility study : 102
Percutaneous vertebroplasty to treat painful myelomatous vertebral deposits - long term efficacy outcomes : 103
An historical review of acute leukaemia in Papua New Guinea, 1958–2007, in preparation for the launch of the melanesian acute leukaemia biology project (MALBP) in 2010 : 104
Comparative outcomes of primary B and T cell non Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract : 105
Orbital relapse of mantle cell lymphoma and response to novel treatment regimens : 106
Rituximab monotherapy in splenic marginal zone lymphoma instead of splenectomy : 107
‘The Lost Tribe’: A retrospective audit of data quality and long-term follow-up arrangements among patients with haematological malignancies at St Bartholomew's Hospital, London (Bart's) : 108
Myeloma: Discretionary laboratory requesting of serum protein electrophoresis is a major source of detection of clinically unsuspected new cases : 109
Antithrombin replacement in adults undergoing induction therapy for acute lymphoblastic leukaemia : 110
The use of locally-defined outcome data demonstrates that a threshold of 10% ZAP70 positive CLL-cells is effective at defining prognostically important subgroups of CLL in a single centre cohort : 111
‘Rainy day’ stem cell harvests: A 5 year experience in two centres : 112
Unexpected high incidence of cerebral sinus thrombosis in patients treated for acute lymphoblastic leukaemia: An unusual year or increasing incidence? : 113
CEPP and R-CEPP chemotherapy in elderly patients with diffuse large B cell lymphoma : 114
Severe 2009 H1N1 influenza in patients with haematological malignancies : 115
A single-centre study of outcomes in patients over 70 years old treated for B-cell diffuse large cell lymphoma (DLBCL); the impact of co-morbidity scores : 116
Epstein-Barr virus driven diffuse large B-cell lymphoma with co-existing follicular lymphoma : 117
Atypical patterns of organ involvement by chronic lymphocytic leukaemia : 118
Single centre experience of the management of post transplant lymphoproliferative disorder : 119
Rituximab induced lung disease: A single centre experience and review of the literature : 120
Does limiting antibiotic prophylaxis improve Clostridium difficile incidence rates in acute haematology patients? : 121
Coverage of haemoglobinopathies in the undergraduate curriculum in the UK : 122
Single dose ferric carboxymaltose compared with iron dextran for the treatment of iron deficiency anaemia : 123
Anaemia and leukopenia in adults with lupus and anti-Ro/anti-La antibodies : 124
The incidence of hypereosinophilia and its clinical significance at a district general hospital : 125
Laboratory haematology validation and utility of the Cellavision DM96-automated digital microscopy haematological cell analysis system : 126
Daptomycin use on a haematology unit in the UK : 127
Pelvic fracture trauma leads to bone marrow dysfunction : 128
National Haematology Undergraduate Teaching Survey: Defining the current state of play and prospects for a core curriculum : 129
End-of-life and haematological malignancy: Destined to die in hospital? : 130
Pilot assessment of malaria diagnosis and education using virtual microscopy for laboratories in Africa and developing nations : 131
Superiority of the QBC over the Diamed OptiMAL-IT as a screening tool for malaria : 132
Haematological characterization in N-Nitroso-N-ethylurea induced tumour bearing rats on oral administration of Pleurotus pulmonarius and P. ostreatus metabolites : 133
Use of an electronic database to monitor complications of Hickman lines in a regional haematology unit : 134
Microbiological surveillance in a regional haematology unit : 135
An audit of the management of neutropenic sepsis at a regional haematology unit : 136
A pilot prospective study of full blood examination parameters in pregnant women in the national capital district of Papua New Guinea : 137
An audit of obstetric cases requiring specialist haematological input, referred during a period of 12 months to a single haematology unit in a medium sized district general hospital, highlighting the importance of specialist obstetric-haematology service in the district general hospital setting : 138
Improved survival in haematological cancer in the Thames Valley Cancer Network : 139
National Cancer Intelligence Network (NCIN) analyses of haematological malignancy. Incidence and survival by sex, ethnicity, deprivation, year of diagnosis and cancer network in the United Kingdom : 140
Evaluation of the validity of UK NEQAS Hb A2 data for the NHS Sickle Cell and Thalassaemia Screening Programme : 141
How well do foundation doctors know how to use oral anticoagulants? : 142
Rapid response of myeloma hyperammonaemic encephalopathy to L-ornithine-L-aspartate therapy : 143
Serum free light chain assay monitoring in plasma cell disorders - a single centre audit : 144
Digital morphology: The UK NEQAS (H) scheme for continuing professional development : 145
Pathology harmony: Consensus reference ranges for blood counts : 146
Evalution of the impact of using the all methods trimmed mean on the performance assessment of haemoglobin estimation in UK NEQAS General Haematology surveys : 147
Manual differential leucocyte counting: An assessment of performance in UK NEQAS General Haematology exercises : 148
Developing an educational library of digital images from blood smears for UK NEQAS(H) : 149
Practical difficulties with conducting non-interventional research for NICE technology appraisals: A case study in a quality of life assessment of chronic lymphocytic leukaemia patients : 150
Five year retrospecitve analysis of septicaemic trends in haemato-oncology admissions to the Ulster Hospital Dundonald : 151
Performance in parasite and blood film surveys by participants in the International External Quality Assessment Scheme for Haematology : 152
Influenza A(H1N1) in patients with haematological malignancies. A review of our experience in South Devon Healthcare NHS Foundation Trust : 153
Malarial episodes in paediatric oncology patients in Senegal: A retrospective, single-centre study : 154
The management of port-a-cath infections in children with severe haemophilia : 155
Near haploidy in ALL masquerading as high hyperdiploidy unmasked by DNA short tandem repeat polymorphism analysis : 156
An evaluation of informed consent and patient understanding of blood transfusion : 157
Abstract withdrawn. : 158
The haemostatic impact of prion reduction in solvent detergent treated plasma : 159
Severe haemolysis due to passenger lymphocyte syndrome after an ABO mismatched bowel transplant - a case report : 160
Developing a new web based haemovigilance data capture system for SHOT : 161
The cost of platelet transfusions: Managing thrombocytopenia of myelodysplastic syndromes in the United Kingdom : 162
Management of haemorrhage associated with cardiac surgery in adults - a survey of protocols in UK centres : 163
Where does blood go? Indications for red cell transfusion in the North of England from 1999 to 2009 : 164
Autologous peripheral progenitor cell harvesting in haematology patients: One centre experience : 165
Anti-insulin receptor antibody mediated hypoglycaemia and insulin resistance following allogeneic stem-cell transplant : 166
Efficacy and toxicity of cyclophosphamide 3 g/m2 and G-CSF for the mobilisation of PBSC in myeloma patients : 167
High prevalence of dyslipidaemia in recipients of both allogeneic and autologous HSCT - a single centre experience : 168
KIR genes are associated with incidence and duration of infection following autologous peripheral blood stem cell transplantation for multiple myeloma : 169
Feasibility of safe ambulatory immediate post-autograft care in a district general hospital : 170
Classic and overlap chronic graft- versus -host disease after T-replete reduced intensity conditioned sibling allograft usually starts within a year, causes prolonged morbidity but low mortality and is influenced by prophylactic methotrexate and ciclosporin dosing : 171
The effects of IL-2 and IL-15 on NKT-cell activation and cytotoxicity against leukaemic cell lines : 172
Weight loss is still a problem with reduced intensity conditioning transplants and modern supportive care : 173
Being underweight may reduce your ability to mobilise stem cells : 174
Fludarabine/cyclophosphamide non-myeloablative allogeneic stem cell transplantation for lymphoid malignancies : 175
Retrospective study of clinical predictors of positive fungal cultures in recipients of allogeneic and autologous stem cell transplantation : 176
Oncolytic reovirus as a treatment for AML : 177
Is Bcr-Abl expression relevant for the survival of cancer stem cells in chronic myeloid leukaemia (CML)? : 178
A novel RUNX1 mutation in an Irish kindred with familial platelet disorder with propensity to acute myeloid leukaemia : 179
Development of a novel DNA vaccine encorporating a PASD1 analogue peptide which can enhance anti-leukaemia T cell responses in vitro and in vivo : 180
Simultaneous analysis of specific T cell populations in acute leukaemia patients using the pMHC array : 181
The clinical significance of protein phosphatase 2A (PP2A) in CML : 182
Molecular responses to tyrosine kinase inhibitors in rare, variant ela2, e6a2 and e19a2 BCR-ABL chronic myeloid leukaemia : 183
CCN3 enhances imatinib induced growth inhibition in chronic myeloid leukaemia : 184
Identification of gene networks associated with acute myeloid leukaemia by comparative molecular methylation and expression profiling : 185
Identification of microRNAs targeting CCN3 in chronic myeloid leukaemia : 186
T-cell and B-cell responses after vaccination against influenza virus and pneumococcus in chronic phase CML patients treated with tyrosine kinase inhibitors : 187
Uptake of synthetic low density lipoprotein by leukaemic stem cells - a potential targeted drug delivery strategy : 188
Global methylation and expression changes in acute myeloid leukemia cell lines reveal clustering patterns after treatment with a demethylating agent : 189
P-CrkL is not a surrogate of Bcr-Abl activity in vitro at short time-points : 190
JAK2 is a relevant target in chronic myeloid leukaemia : 191
5-aza-2′-deoxycytidine, a DNA methylation inhibitor, induces miRNA expression changes in acute myeloid leukaemia cell lines : 192
Identification of a HOX-associated prognostic signature in AML : 193
Coexistence of JAK2 positive myeloproliferative disorder and CML, a lesson from clinical practice : 194
An audit of clinical practice in the diagnosis of myelodysplastic syndromes at UK haematology centres : 195
Detection and referral of serum paraproteins identified by discretionary testing : 196
Invasive pulmonary aspergillosis in hemato-oncology patients-early diagnosis by thoracic high resolution CT : 197
English NHS in-patient bed days by cancer type (1997-2004): The impact of haematological malignancies : 198
An analysis of AML treatment in a regional leukaemia unit: Nov 2006-Nov 2009 : 199
Adherence to imatinib therapy is the critical factor for achieving molecular responses in patients with chronic myeloid leukaemia : 200
Imatinib plasma levels do not have prognostic value in determining molecular responses when adherence to therapy is taken in account in CML patients on long term imatinib treatment : 201
Analysis of factors affecting outcome in recipients of bone marrow transplantation for myelodysplasia; a single centre's experience over a nine year period : 202
Imatinib efficacy and tolerability in a ‘real world’ CML population study: Results from a West of Scotland and Lothian retrospective survey : 203
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia : 204
An audit on the management of chronic myeloid leukaemia : 205
Audit on the use of bortezomib {velcade} in cases of relapsed or refractory myeloma at Southampton General Hospital : 206
Recurrence of pleural effusion on bosutinib therapy in a dasatinib treated patient with chronic myeloid leukaemia : 207
A district general's experience on the toxicity associated with bortezomib therapy in myeloma : 208
Efficacy and tolerability of dasatinib as a second line therapy for chronic myeloid leukaemia in the west of Scotland : 209
Significant weight gain in patient with chronic myeloid leukaemia treated with imatinib therapy : 210
Abstract withdrawn. : 211
Ribavirin made easy. A collaborative approach to the development of guidance documents for the delivery of nebulised ribavirin using the Aiolos device : 212
Improving the quality of peripheral neuropathy assessments for myeloma patients : 213
‘Hospital 2 Home’. Getting it right for young people with cancer : 214
“Getting the best of both worlds?” Uniting adult and paediatric practice in the treatment of febrile neutropenia : 215
Improving the assessment of peripheral neuropathy in patients recieving thalidomide for multiple myeloma : 216
Increased expression of YY1 protein predicts favourable outcome in follicular lymphoma : 217
Mechanisms of oncolytic measles virus-induced neutrophil-mediated cytotoxicity : 218
The polo like-kinase inhibitor BI2536 exhibits potent activity against plasma cells and represents a novel therapy in multiple myeloma : 219
13q deletion size predicts disease progression and time to first treatment in patients with chronic lymphocytic leukaemia : 220
A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines : 221
MicroRNA-155 and microRNA-29c are upregulated in chronic lymphocytic leukaemia : 222
Investigating minimal residual disease in chronic lymphocytic leukaemia using fluorescent in situ hybridisation : 223
Differential sensitivity of ATM mutant chronic lymphocytic leukaemia (CLL) cells to acetaminophen-induced cytotoxicity as a consequence of impaired redox stress responses : 224
The serotonin receptor antagonist ondansetron up-regulates the production of nitric oxides in acute lymphoblastic leukaemia cells : 225
Proteomics as a tool to determine the mechanisms of action of the B-cell receptor and identify novel prognostic biomarkers in chronic lymphocytic leukaemia : 226
Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: A potential therapy for poor risk B-cell chronic lymphocytic leukaemia : 227
rs1045642 in P-glycoprotein; from genome to proteome in plasma cell myeloma : 228
Evidence for a macromolecular complex in poor prognostic chronic lymphocytic leukaemia (CLL) that contains CD38, CD49d, CD44, MMP-9 And ZAP-70 : 229
Genome-wide analysis of chromosomal alterations in chronic lymphocytic leukaemia : 230
The role of MDR1 (ABCB1) gene single nucleotide polymorphisms in chronic lymphocytic leukaemia : 231
CD49d is an independent prognostic marker for time to first treatment and overall survival in chronic lymphocytic leukaemia (CLL) : 232
Improving chelation therapy by monitoring T2* MRI cardiac scores and ferritin values in regularly transfused patients with thalassaemia : 233
Management of acute chest syndrome in patients with sickle cell disease : 234
Abstract withdrawn. : 235
Abstract withdrawn. : 236
What is missing? : 237
Diagnostic and therapeutic challenges of an acute presentation of a rare unstable haemoglobin variant : 238
An audit of the uptake of pneumococcus vaccination in adults with sickle cell disease : 239
Spectrum of thalassaemia syndromes and structural hemoglobin variants encountered in a referral hospital in North India : 240
An audit of the management of polycythaemia in a district general hospital : 241
Trends in myocardial haemosiderosis relate to vitamin D status in transfusionally iron overloaded patients : 242